Literature DB >> 1987374

Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus.

T Kanesaki1, B R Murphy, P L Collins, P L Ogra.   

Abstract

Cotton rats were immunized via intranasal, intradermal, or enteric routes with respiratory syncytial virus (RSV) or a live recombinant vaccinia virus expressing the RSV F glycoprotein (vaccinia F). The animals were tested for the appearance of RSV-specific antibody responses in the serum, bronchoalveolar lavage, and nasal wash after immunization and for virus replication 4 days after intranasal challenge with RSV. RSV antibody response in the serum and respiratory tract was demonstrated in all immunization groups and was significantly increased after intranasal challenge with RSV. Immunoglobulin A (IgA) antibody response in bronchoalveolar lavage fluid after intranasal or enteric immunization was two- to threefold higher than that after intradermal immunization. Nasal-wash IgA antibody response was not significantly different among three immunization groups, although mean antibody titer was the highest in intranasal immunization group. Complete resistance to replication of RSV challenge was observed in the lungs of cotton rats immunized by the intranasal or enteric routes, whereas a low level of replication was detected in the lungs of rats immunized intradermally. Enteric or intradermal immunization conferred partial protection to the upper respiratory tract, but complete protection of the upper respiratory tract was observed in the intranasal immunization group. These observations suggest that while enteric immunization is quite effective in inducing antibody responses in the respiratory tract, the magnitude of antiviral immunity induced in the respiratory tract after intranasal immunization may be superior to that observed after enteric immunization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987374      PMCID: PMC239804     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Maternal determinants of neonatal immune response to ovalbumin: effect of breast feeding on development of anti-ovalbumin antibody in the neonate.

Authors:  Y Okamoto; J Freihorst; P L Ogra
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

2.  Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses.

Authors:  T J Smith; E L Buescher; F H Top; W A Altemeier; J M McCown
Journal:  J Infect Dis       Date:  1970-10       Impact factor: 5.226

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

5.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

6.  Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine.

Authors:  P L Ogra; D T Karzon
Journal:  J Immunol       Date:  1969-06       Impact factor: 5.422

7.  Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.

Authors:  B R Murphy; P L Collins; L Lawrence; J Zubak; R M Chanock; G A Prince
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

8.  Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.

Authors:  E J Stott; G Taylor; L A Ball; K Anderson; K K Young; A M King; G W Wertz
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

9.  An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test.

Authors:  H V Coates; D W Alling; R M Chanock
Journal:  Am J Epidemiol       Date:  1966-03       Impact factor: 4.897

10.  Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children.

Authors:  H W Kim; J O Arrobio; C D Brandt; P Wright; D Hodes; R M Chanock; R H Parrott
Journal:  Pediatrics       Date:  1973-07       Impact factor: 7.124

View more
  11 in total

1.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors.

Authors:  Anne Keriel; Céline René; Chad Galer; Joseph Zabner; Eric J Kremer
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Immunization against rabies with plant-derived antigen.

Authors:  A Modelska; B Dietzschold; N Sleysh; Z F Fu; K Steplewski; D C Hooper; H Koprowski; V Yusibov
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 5.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 6.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.

Authors:  Rajesh Thippeshappa; Baoping Tian; Brad Cleveland; Wenjin Guo; Patricia Polacino; Shiu-Lok Hu
Journal:  Clin Vaccine Immunol       Date:  2015-12-30

Review 8.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

9.  Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes.

Authors:  T Matsuoka; Y Okamoto; Z Matsuzaki; S Endo; E Ito; H Tsutsumi; R A Williamson; H Sakurai; D R Burton; I Saito
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

10.  Enteric immunization of mice against influenza with recombinant vaccinia.

Authors:  C A Meitin; B S Bender; P A Small
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.